EyePoint Analyst Price Targets - Benzinga

SPY774.46+0.07%QQQ747.75+0.02%BTC/USD82,103.78+0.50%DIA511.79+0.03%GLD379.46+0.22%TLT77.66−0.27%

EyePoint Inc

EYPTNASDAQ

Trade with Public

Trade with Public

$3.46

0.144.22%

Last update: Oct 8, 6:38 PM

$3.50

0.185.42%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

EyePoint Analyst Price Targets

Wall Street analyst price targets and consensus rating for EyePoint (EYPT).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

8Buy

5Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$27Upside to Avg. PT+673.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	TD Cowen	Tara Bancroft	Downgrade	Buy→Hold	$20→$4
Aug 18, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$35→$17
Aug 18, 2026	RBC Capital	Lisa Walter	Downgrade	Outperform→Sector Perform	$37→$5
Aug 18, 2026	Chardan Capital	Andreas Argyrides	Downgrade	Buy→Neutral	$65→$5
Aug 18, 2026	HC Wainwright & Co.	Yi Chen	Downgrade	Buy→Neutral	—
Aug 17, 2026	JP Morgan	Tessa Romero	Downgrade	Overweight→Neutral	—
Aug 17, 2026	Jefferies	Kambiz Yazdi	PT Cut	Buy	$30→$8
Aug 17, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$65
Aug 7, 2026	Chardan Capital	Andreas Argyrides	Maintained	Buy	$65
Aug 6, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$47→$55
Aug 6, 2026	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$30→$27
Jul 16, 2026	Stifel	Annabel Samimy	Initiate	Buy	$40
Jul 8, 2026	Cantor Fitzgerald	Steve Seedhouse	Assumes	Overweight	$47
Jul 1, 2026	Chardan Capital	Andreas Argyrides	PT Raise	Buy	$29→$65
Jun 24, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$68
May 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$39→$37
Mar 9, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$35
Mar 5, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$23→$30
Mar 4, 2026	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$27→$29
Nov 6, 2025	RBC Capital	Lisa Walter	PT Raise	Outperform	$28→$39

More with Benzinga EdgeGet Access

Analyst Ratings News

This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday

Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.

Avi Kapoor

PRO
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4

TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.

Benzinga Newsdesk

These Analysts Slash Their Forecasts On EyePoint

EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.

Avi Kapoor

PRO
Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17

Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $35 to $17.

Benzinga Newsdesk

PRO
RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5

RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.

Benzinga Newsdesk

PRO
Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5

Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.

Benzinga Newsdesk